Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ:BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6% higher at $102.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of BioNTech SE (Symbol: BNTX) entered into oversold territory, hitting an RSI reading of 29.3 ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form Confirming validity of ...

As a Venture Partner at Third Rock Ventures, she led teams in creating new oncology drug discovery companies, including Tango Therapeutics, Neon Therapeutics (acquired by BioNTech (Nasdaq ...

BioNTech (NasdaqGS:BNTX) saw its share price increase by 11%, coinciding with significant market activity and major index gains. While the company itself did not have any significant news or ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...

BioNTech SE Sponsored ADR (BNTX), another stock in the same industry, closed the last trading session 3.7% higher at $96.52. BNTX has returned -4.5% in the past month. For BioNTech, the consensus ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Despite the competition, we believe Summit enjoys the advantage of being ahead in clinical development over the BioNTech and Instil Bio therapies. The BNTX and TIL candidates are still at least a ...